Medtronic, a healthcare technology company based in Ireland, plans to separate its diabetes business into a standalone, publicly traded company by the end of 2026.
The company announced the move May 21, noting the new entity will be a direct-to-consumer business and “the only company to commercialize a complete intensive insulin management ecosystem,” according to a news release.
The diabetes unit employs more than 8,000 people worldwide and represented 8% of Medtronic’s fiscal year 2025 revenue.
